# Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

> **NCT06312644** · — · RECRUITING · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 75 (estimated)

## Conditions studied

- Ultomiris-exposed Pregnant/ Postpartum
- Pregnancy
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Generalized Myasthenia Gravis (gMG)
- Neuromyelitis Optica Spectrum Disorder (NMOSD)

## Interventions

- **DRUG:** Ultomiris

## Key facts

- **NCT ID:** NCT06312644
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-16
- **Primary completion:** 2034-07-11
- **Final completion:** 2034-07-11
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06312644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06312644, "Study of Ultomiris® (Ravulizumab) Safety in Pregnancy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06312644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*